Special issue: Molecular mechanisms of insulin resistance in peripheral tissues

Metabolic and molecular mechanisms of macrophage polarisation and adipose tissue insulin resistance

Orliaguet L¹, Ejralmanesh T¹, Alzaid F¹
¹ Cordeliers Research Centre, INSERM, IMMEDIAB Laboratory, Sorbonne Université, Université de Paris, F-75006, Paris, France.

Abstract

Inflammation plays a key role in the development and progression of type-2 diabetes (T2D), a disease characterised by peripheral insulin resistance and systemic glucolipotoxicity. Visceral adipose tissue (AT) is the main source of inflammation early in disease course. Macrophages are innate immune cells that populate all peripheral tissues, including AT. Dysregulated AT macrophage (ATM) responses to microenvironmental changes are at the root of aberrant inflammation and development of insulin resistance, locally and systemically. The inflammatory activation of macrophages is regulated at multiple levels: cell surface receptor stimulation, intracellular signalling, transcriptionally and metabolically. This review will cover the main mechanisms involved in AT inflammation and insulin resistance in T2D. First, we will describe the physiological and pathological changes in AT that lead to inflammation and insulin resistance. We will next focus on the transcriptional and metabolic mechanisms described that lead to the activation of ATMs. We will discuss more novel metabolic mechanisms that influence macrophage polarisation in other disease or tissues contexts that may be relevant to future work in insulin resistance and T2D.

Key words:

Adipose tissue
Inflammation
Insulin resistance
Immunometabolism
Macrophages
Type-2 diabetes
T2D
Metabolic and molecular mechanisms of macrophage polarisation and adipose tissue insulin resistance

Orliaguet L¹, Ejlalmanesh T¹, Alzaid F¹

¹ Cordeliers Research Centre, INSERM, IMMEDIAB Laboratory, Sorbonne Université, Université de Paris, F-75006, Paris, France.

Introduction: Physiology and pathology of adipose tissue

The physiological role of adipose tissue (AT) is long-term energy storage in the form of fat, depending on the AT depot, this fat also provides protection and insulation. AT is also an endocrine organ and responds to endocrine signalling to regulate appetite and to control systemic lipid homeostasis. Persistent overnutrition over time leads to adipose tissue expansion, phenotypic alterations and changes in sensitivity to hormone signalling.

AT is composed of two main fractions: the adipocyte fraction and the stromal vascular fraction (SVF). The adipocyte fraction is the main component that regulates energy stores and systemic lipid homeostasis. The SVF fraction is heterogenous in composition and changes over time in response to altered metabolic needs. The SVF is composed of mesenchymal progenitor/stem cells, preadipocytes, fibroblasts, endothelial cells, and immune cells including macrophages (1). Macrophages represent one of the most dynamic cells in this fraction of adipose tissue and are key actors of inflammation and in the development of insulin resistance.

Under physiological conditions AT macrophages (ATMs) represent approximately 2% of the cells in AT. Throughout the development of obesity, insulin resistance and type-2 diabetes (T2D), ATMs increase in number to represent up to 50% of cells in AT (1). The increase in ATM numbers is due to proliferation and to the recruitment of circulating monocytes that differentiate in situ into macrophages. The increase in ATM number is accompanied by an altered phenotype. Whilst macrophages in the lean and metabolically healthy state are alternatively activated (M2-like or anti-inflammatory phenotype); macrophages in the obese insulin resistant state are classically or metabolically activated (M1-like, pro-inflammatory or intermediate phenotypes) (2-4). The increased number and change in polarisation are accompanied by an increase in pro-inflammatory cytokines, in the microenvironment and systemically.

Adipose tissue inflammation and insulin resistance

Studies in the 1990s drew the earliest links between inflammation and adipose tissue insulin resistance. Hotamisligil et al and Uysal et al demonstrated that the pro-inflammatory cytokine tumour necrosis factor (TNF) was highly expressed in AT of obese rodents and that this cytokine was causally linked to insulin resistance by direct interference with insulin receptor signalling (5-7).

Finding the precise triggers of this inflammatory response is an area of active research. However, expanding AT does provide a number of potential cues that can influence macrophage polarisation. For example, adipocyte death or senescence, hypoxia, increased lipolysis or mechanical stress; recent research has even implicated insulin resistance itself in the initiation of inflammation (8). Indeed, it is important to note that over long-term diet-induced obesity, two phases of insulin resistance do exist, an early phase that is independent of inflammation and an inflammation-dependent late phase of insulin resistance (9).
Insulin exerts its effects through binding to its cell surface receptor, which undergoes autophosphorylation. Phosphorylation of 3 tyrosine residues is necessary for amplification of kinase activity that recruits insulin receptor substrate (IRS) proteins important for the signalling pathway. Downstream of these events, phosphatidylinositol-3-kinase (PI3K) and Mitogen-activated protein kinase (MAP-kinase) mediate the metabolic and mitogenic actions of insulin in the cell (10).

Insulin resistance is a result of failure of one or more of these mechanisms, resulting in decreased glucose uptake, glycogen synthesis (mainly by the liver) and increased lipolysis in AT. Resulting hyperglycaemia and dyslipidaemia potentiate insulin secretion from the pancreas. If sustained, this vicious cycle results in beta cell failure, frank T2D and increased risk of complications and comorbidities. Chronic inflammation has been consistently reported to underpin all these changes that lead to insulin resistance and T2D (11-13). With numerous other studies demonstrating that blunting the inflammatory response, mitigates metabolic decline, preserves glycaemic homeostasis or even reverses insulin resistance (13-15).

Molecular mechanisms of inflammation and insulin resistance

With ATMs being the central mediators of inflammation, much research has worked to decipher the mechanisms that control inflammatory polarisation and insulin resistance in the microenvironment. Multiple layers of regulation exist, from cell surface receptors to nuclear receptors, transcription factors and their co-regulators (16). The multiple levels of complexity converge to the activation of two main inflammatory pathways: JNKs (c-Jun N-terminal kinases) and NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) (17-19). These two pathways are active and exert their effects in both adipocytes and in macrophages (Figure 1).

Activation of these pathways leads to the production of pro-inflammatory cytokines, chemokines and chemoattractants that promote the recruitment of monocytes. Once recruited to AT, monocytes are exposed to the inflammatory milieu and differentiate in situ. These monocyte-macrophages may be phenotypically and functionally distinct from resident macrophages and are termed infiltrating macrophages (20). Infiltrating macrophages amplify the local and systemic inflammatory responses that contributes to impaired insulin signalling (21).

JNK and NFκB Inflammatory pathways in adipocyte insulin resistance

JNK is expressed in myeloid cells and in insulin target cells. JNK activation in myeloid cells results in the transcription of pro-inflammatory mediators. JNK responds to a number of stimuli, including inflammatory cytokines, free fatty acids, or intracellular signalling, such as the unfolded protein response (22,23). Importantly, in insulin-target cells, JNK activation can inhibit the insulin signalling pathway through serine-threonine phosphorylation and inhibition of IRS-1. This results in inhibiting PI3K/protein kinase B (PKB) signalling downstream of IRS1. This role was deciphered with the use of JNK1 deficient mice, specific to adipose tissue (24-26).

With regards to NFκB, under physiological conditions, NFκB proteins are retained in the cytoplasm by inhibitors of κB (IκBs). Regulated proteasomal degradation of IκBs allows the nuclear translocation of NFκB; this leads to the transcription of canonical inflammatory mediators, such as interleukin (IL)-6, TNF, interferons and importantly the monocyte chemoattractant protein-1 (CCL2/MCP1) which is central to monocyte recruitment (27,28). Adipocyte-specific IKKβ deletion, the proteins that mediate IκB degradation; results in a lack of responsiveness to fatty...
acids and a blunted inflammatory signature. Similarly, IKKβ overexpression in adipocytes decreases expression of anti-inflammatory molecules (leptin and adiponectin) (29).

**Inflammatory pathways in adipose tissue**

Innate immune cells, such as macrophages, mount their inflammatory responses following stimulation of pattern recognition receptors (PRRs). PRRs are composed of two main families: Toll-like and NOD-like receptors (TLRs and NLRs). These receptors span cell surface and intracellular membranes and they are ligated by damage- or pathogen-associated molecular patterns (DAMPs or PAMPs). In the case of metabolic diseases, stimulation is by DAMPs generated by dysmetabolism, such as fatty acids, hyperglycaemia, cellular senescence or other stress signals (30).

Macrophages play a key role in amplifying inflammation in the adipose microenvironment. Once activated, secreted cytokines act both locally and peripherally to increase inflammation and insulin resistance (30). Two main pathways are important actors of inflammation: the NLRP3 inflammasome and Interferon signalling.

**The NLRP3 inflammasome**

NLRP3 (gene encoding NALP3: NACHT, LRR and PYD domains-containing protein 3) is a NLR highly expressed in ATMs that form crown-like structures around senescent adipocytes upon diet-induced obesity (31). NLRP3 and the adaptor protein ASC form a caspase-1 activating complex known as the NLRP3 inflammasome; the inflammasome complex is a sensor for metabolic homeostasis (32). Activation of caspase-1 by this complex results in the maturation and release of IL1B and IL18; two potent inflammatory cytokines of the IL1 family. Mice deficient for NLRP3 are protected from diet-induced insulin resistance due to failure to form the inflammasome complex; similarly, therapeutic intervention for weight loss in obesity and T2D reduces expression of NLRP3 and its target cytokines (31).

IL1B is a key inflammasome product, a cytokine heavily involved in the development of T2D at multiple levels. Increased expression of IL1B is associated with insulin resistance as well as in the destruction of pancreatic beta cells in more advanced disease (33). In AT, IL1B suppresses insulin signalling in adipocytes, exposure to IL1B results in decreased insulin stimulated glucose uptake and lipogenesis (34). Glucose transporter (GLUT)-4 expression and translocation are also repressed (35,36).

IL1B exerts its effects by binding to its receptor and recruiting a coreceptor to form a heterodimer-receptor transmembrane complex. The cytoplasmic IL1R domain initiates intracellular signalling by recruiting the adaptor proteins MyD88 (myeloid primary response differentiation-88 protein) and IRAK (interleukin 1 associated kinase). Downstream of these adaptor proteins are the MAPK and NFκB signalling pathways, which are effectors or inflammatory and insulin desensitisation.

IL18, another cytokine released by the inflammasome and member of the IL1 superfamily, is expressed in both immune and non-immune cells and is known to potentiate interferon signalling. Similar to IL1B, IL18 recruits the MyD88 adaptor protein and the inflammatory NFκB pathway. IL18 is released by AT and its circulating levels increase in obesity and T2D (37,38). IL18 accelerates maturation of other immune cells, including T- and NK-cells, and enhances the production of other pro-inflammatory cytokines which exacerbate systemic inflammation in obesity and insulin resistance (39).

**IL6 and TNF**
IL6 is an inflammatory cytokine involved in the development of insulin resistance (40). IL6 expression characterises sepsis, mediating fever and the acute phase response. Mostly produced from macrophages, IL6 can also be released in small amounts by adipocytes; in AT IL6 stimulates energy mobilisation and increases temperature. Upon interaction with its receptor, IL6 activates the JAK1-STAT3 (Janus Kinase-signal transducer and activator of transcription) pathway (41). In AT during obesity and insulin resistance, IL6 exposure impairs insulin signalling by interfering with IRS phosphorylation, thus increasing adipocyte lipolysis which promotes hepatic gluconeogenesis and insulin resistance (42-45). Although physiological and positive effects of IL6 action have also been reported (increased satiety, leptin release, IL4R expression in macrophages), the aberrant IL6 expression in diet-induced obesity results in chronic activation of its inflammatory axis.

Tumour necrosis factor (TNF) is an inflammatory cytokine expressed in two forms: a transmembrane form that mediates autocrine and paracrine signalling; and a soluble form that mediates endocrine signalling. The levels of both forms are increased in AT in obesity and insulin resistance with the main source being ATMs (46,47). TNF interacts with the receptors TNFR1 and TNFR2; both receptors can also be cleaved creating soluble forms thought to neutralise and clear soluble TNF from circulation (48). Ligation of TNFR1 mediates the majority of effects on adipocytes (49). TNFR2 has been shown to contribute in a limited manner to altering adipocyte function, notably reducing GLUT4, IRS-1 and -2 expression, inducing apoptosis or contributing to JNK activation (50-52). Both TNFRs exert their effects through signal transduction and adaptor protein recruitment. The effects of TNF include inducing adipocyte and pre-adipocyte apoptosis, with pre-adipocytes being more sensitive (53). Signalling downstream of TNFR also includes activation of NFκB and MAPK cascades and are leading candidates for mediating TNF-related metabolic dysregulation (54,55). TNF action is associate with suppression of the insulin receptor, IRS-1, -2 and GLUT4, through multiple mechanisms, including proteasomal degradation, impaired translocation and direct transcriptional repression. (56-58)

**Transcriptional control of ATM polarisation**

**Signal transducers and activators of transcription: JAK-STAT signaling**

The JAK family of proteins interact with cytokine and growth factor receptors and mediates signalling to STAT proteins. STATs are a family of 7 proteins, that form part of the interferon signalling system, and have a cell- and tissue-specific distribution (59-61). The JAK-STAT axis controls a large number of metabolic pathways in AT and is dysregulated in diet-induced obesity and insulin resistance (41,62). STATs expressed in M2-like macrophages have been implicated in buffering pro-inflammatory polarisation in T2D (Figure 2); whereas STATs in M1-like macrophages have not been directly linked to T2D.

STAT activity is regulated by cytokines and growth factors, which once signalled to membranes initiate JAK-mediated phosphorylation of STATs allowing their dimerization and nuclear translocation. STAT1 and STAT5 induce M1-like polarisation of macrophages whereas STAT3 and STAT6 induce M2 macrophage polarisation. Whilst macrophage STAT1 has not been reported to play a role in obesity or insulin resistance, in vitro and ex vivo studies demonstrated that STAT1 is activated in response to high glucose where a large epigenetic component is attributed to its function (63). Similarly, no conclusive studies have linked STAT5 to T2D pathogenesis to our knowledge.
M2 polarising STATs are more closely associated to T2D and its complications. STAT3 is a downstream target of metformin. Metformin inhibits differentiation of monocytes to macrophages through AMPK-mediated inhibition of STAT3, this also resulted in decreased monocyte infiltration into atherosclerotic plaques and an ameliorated outcome in mice (64). In other studies, a model of myeloid-specific deficiency of JAK2, reduced phosphorylation of STAT3 and led to a less inflammatory and healthier visceral AT phenotype upon diet-induced obesity and insulin resistance (65). Mice deficient for STAT6 are more prone to diet-induced obesity and increase in oxidative stress and inflammation in AT, increasing susceptibility to insulin resistance and T2D (66).

**Type-1 interferon signalling and transcription control**

The type-1 interferons (IFN) are a large family of proteins that regulate the multiple components of the immune system and were initially characterised as the host response to viral infection. IFNs signal danger to cells in proximity causing them to heighten their anti-viral defences (67). However, over the years, several other roles have been attributed to IFNs, mainly in auto-immune and metabolic diseases. In macrophages, and other cells of the myeloid system, type-1 IFNs (IFNα, β, κ and ω) are expressed (68). They are stimulated downstream of TLR-ligation, canonically by bacterial or viral stimuli, whereas the stimuli in metabolic diseases remain to be elucidated. Macrophage type-1 IFN expression is tightly regulated by two transcription factors, the IFN regulatory factors (IRF)-4 and -5 (Figures 1 and 2). Many studies have solidified the roles of these two transcription factors in the pathogenesis of T2D (69). Classical polarisation of macrophages is promoted by IRF5, whereas pro-resolution, alternative activation is driven by IRF4 (70). In ATMs, IRF5 is instrumental in mediating metabolic inflammation, leading to maladaptive AT expansion and the development of insulin resistance (13). Mice with a myeloid-deficiency of IRF5 have improved metabolic homeostasis upon high-fat feeding, lower AT inflammation and redistribution of AT from the visceral depot towards the subcutaneous depot. This phenomenon is mediated by alternatively activated macrophages that restrict adipocyte growth and promote a hyperplastic and metabolically protective response upon diet-induced obesity. Interestingly this phenotype is comparable to that of TLR4-deficient mice, indicating that the TLR4-IRF5 axis of macrophage polarisation may be conserved in metabolic inflammation (71). With regards to IRF4, deficiency in myeloid cells results in mice with exuberant AT inflammation and decreased insulin sensitivity when compared to IRF4-competent mice upon diet-induced obesity despite no differences in weight gain (72). Interestingly, IRF4 is also expressed in adipocytes, where it is required for lipolytic programming; mice lacking IRF4 in adipocytes are predisposed to increased weight gain and adiposity and deficient lipolysis (73).

**Metabolic mechanisms of macrophage polarisation**

Macrophage cellular metabolism, or bioenergetic adaptation, also strongly influences effector functions. Canonically, pro-inflammatory polarisation is associated with glycolytic metabolism whereas anti-inflammatory or pro-resolution polarisation is associated with oxidative or mitochondrial metabolism (Figures 1 and 2). These metabolic pathways and the associated functions have been established in recent years with the application of model systems (such as bone marrow derived macrophages) treated with model immunogens or cytokines. The exact stressors in a diabetogenic context and the specific metabolic adaptations of tissue macrophages in situ remains to fully deciphered. The particularity of diabetogenic conditions is the systemic abundance of metabolic substrates in hyperglycaemia and dyslipidaemia. Moreover, AT is particularly rich in lipids and lipolysis products at the onset of insulin resistance and thus
ATMs are expected to have particular adaptations to this microenvironment and metabolic milieu.

**Glycolysis in macrophage polarisation**

Typically, in predominantly glycolytic macrophages, that are pro-inflammatory, the rapid influx of glucose is supported by upregulation and plasma membrane localisation of GLUT1 (74). However, in some primary macrophage subsets, the increased uptake and metabolism of glucose has been shown to be dissociable from inflammation, notably in lipid-rich microenvironments such as in atherosclerotic plaques (75). GLUT1 is indeed expressed in AT and specifically in ATM that form crown-like structures over the course of diet-induced obesity, however a specific role for GLUT1 in ATM function or the development of insulin resistance remains to be validated (Figure 1).

Components of the glycolytic pathway have alternate functions in macrophages that interact with transcriptional and inflammatory machinery that influence polarisation. Hexokinase (HK)-1, is a key enzyme that phosphorylates glucose to produce glucose-6-phosphate as the first step of glycolysis. In macrophages HK1 promotes NLRP3 inflammasome formation and supports IL1B secretion, in collaboration with the mammalian target of rapamycin complex (mTORC)-1 (76).

The hypoxia sensor hypoxia-inducible factor (HIF)-1-α is an important link between glycolytic programming and inflammation. HIF1α is stabilised in macrophages by succinate, a metabolite of the tricarboxylic acid (TCA) cycle that accumulates with increasing glycolytic flux (77). The stabilisation of HIF1α allows for its transcriptional activity to take place, inducing expression of GLUT1 as well as the expression of inflammatory mediators such as IL1B, with the pyruvate kinase isoenzyme (PKM)-2 as a coregulator. PKM2 canonically catalyses the last step of glycolysis, being responsible for net ATP and pyruvate production. In M1 macrophages it also acts as a transcriptional coregulator (78,79). The HIF1α pathway has itself been validated to play a role in metabolic diseases, where HIF1α deficient mice are protected against diet-induced obesity and insulin resistance.

Another glycolytic enzyme that influences inflammation is Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). GAPDH binds TNF at the mRNA level and post-transcriptionally represses its expression in monocytes (80). When glycolysis is up-regulated, GAPDH is recruited to carry out its metabolic function, and this releases its break on TNF mRNA, allowing maturation and release of the cytokine in its active form.

The carbohydrate kinase-like (CARKL) protein is downregulated in classical macrophages. Downregulation channels the flux of glycolytic intermediates through the pentose phosphate pathway (PPP). Increased PPP activity generates substrates for protein and nucleotide synthesis, as well as the production of NADPH and NADPH oxidase-mediated ROS (81). These activities support cytokine synthesis and generation of products necessary for bacterial killing.

As well as metabolic enzymes and metabolites that interact with inflammatory machinery, inflammatory transcription factors, namely IRF5, have been implicated in the control of cellular metabolism. Two separate mechanisms have been demonstrated for the role of IRF5 in cellular metabolism, the impairment of efferocytosis and the promotion of glycolysis. Seneviratne et al demonstrated that IRF5 supports foam cell formation in atherosclerosis by inhibiting necrotic core formation, this would lead to an increase and possible overload of substrates in lipid-laden macrophages (82). Conversely, genetic risk-variants that increase IRF5 expression are associated with increased glycolysis in bone-marrow derived macrophages (83). Such
mechanisms clearly work in parallel to IRF5’s main function as a transcription factor promoting M1 polarisation.

Much less frequently, glycolysis has also been reported in alternatively activated macrophages. Precisely, macrophage stimulation with IL4 and MCSF lead to activation of mTORC2 and the upregulation of glycolysis through IRF4 (84). However, a subtle difference in the glycolytic programming of alternatively activated macrophages is that glycolysis products are directed towards mitochondria rather than towards the PPP. This supports the TCA cycle and mitochondrial oxidative phosphorylation (OXPHOS); accordingly other studies have shown that 2-deoxyglucose mediated inhibition of glycolysis also attenuates mitochondrial metabolism and M2 marker expression in response to IL4 (85).

**Mitochondria and mitochondrial respiration in macrophage polarisation**

Mitochondria have numerous functions beyond their roles in oxidative metabolism, such as dictating levels of oxidative stress, calcium signalling, apoptosis, inflammation as well as cellular and systemic metabolism. Altered mitochondrial function and reduced mitochondrial DNA have been reported in murine models of genetic obesity (86); with decreases in mitochondrial activity also reported in human AT from obese individuals (87). A general mechanism by which mitochondria contribute to inflammation is interaction with redox sensitive pathways in the cell. Mitochondrial dysfunction leads to aggravated inflammation through activation of redox-sensitive inflammatory mechanisms, such as NFκB or the NLRP3 inflammasome (88,89). Mitochondrial dysfunction is also associated with accumulation of ectopic or excess lipids, interfering with insulin signalling and leading to adipocyte hypertrophy and hypoxia, respectively (90).

In terms of metabolism, mitochondria metabolise lipids as well as glycolysis end-products. Increased lipid uptake and oxidation characterise alternatively activated macrophages following IL4 stimulation (91). Indeed, inhibition of fatty acid oxidation (FAO) or OXPHOS attenuates expression of M2 markers (92,93). In the case of IL4 stimulation metabolic reprogramming of M2 polarisation is mediated by STAT6 and the peroxisome proliferator-activated receptor gamma (PPARγ), coactivator 1 beta (PGC1B) (94). The substrates for FAO are exogenous lipids taken up by CD36 or are synthesised by lipogenic machinery of the cell. An additional important step for metabolising lipid imported into the cell by CD36, is their lipolysis by the lysosomal acid lipase (LAL). LAL deficiency or treatment by orlistat, a lipolysis inhibitor, decreases macrophage oxidative respiration and impairs alternative polarisation (95).

Fatty acid transporters (FATP1) and fatty acid binding proteins (FABP4/5) also influence macrophage polarisation (95,96). Macrophage-deficiency of FATP1 biases cellular respiration towards glycolysis and primes polarisation towards a pro-inflammatory phenotype; which is reflected in vivo by an aggravated metabolic phenotype in diet-induced obesity. Interestingly, the deletion of FABP4/5 in macrophages results in a metabolically protective phenotype. This indicates that FABPs may contribute more to signal transduction from a dysmetabolic environment than to substrate provision for oxidative cellular respiration.

Mitochondrial enzymes themselves contribute to regulation of cellular metabolism and macrophage fate (Figure 2). Carnitine palmitoyl transferase (CPT)-1 is an enzyme essential for movement of substrates from the cytoplasm to the mitochondria for their metabolism. Overexpression of CPT1 increases FAO while decreasing triglyceride content and production of pro-inflammatory cytokines (97). Alternatively, the loss of CPT2 in macrophages results in de-
creased FAO with no functional consequence on the IL4-stimulated alternative activation phenotype (93,98). Similarly, etomoxir inhibition of FAO does not affect alternative activation of macrophages. Taken together these data indicate that CPT1 has specific properties that mediate anti-inflammatory/alternative polarisation, which may only be fuelled or potentiated by the other components of the CPT-FAO axis. Alternatively, FAO and CPT2 may play more significant roles in regulating redox status, or in tempering and resolving pro-inflammatory polarisation.

**TCA cycle and intermediates in macrophage polarisation**

The TCA cycle plays a central role in both pro- and anti-inflammatory polarization. Under classical activation, the TCA cycle is interrupted at two steps that result in decreased alpha-ketoglutarate (αKG) production and accumulation of succinate and citrate. Citrate is exported to the cytoplasm as a substrate for lipogenesis, where products are alarmins and pro-inflammatory mediators such as prostaglandin E2 and nitrous oxide (99). Citrate can also be converted to itaconate through the enzyme Immune responsive gene (IRG)-1. Iaconate is a metabolite that inhibits SDH and allowing the accumulation of succinate (100). The accumulation of succinate stabilizes HIF1α, which is an integral part of glycolytic and inflammatory programming. Moreover, in the presence of oxygen, succinate oxidation also provides a source of mitochondrial ROS necessary for anti-bacterial activity (101). More recently another mechanism described autocrine as well as paracrine roles of succinate signalling, where succinate can be secreted by the succinate receptor (SUCNR)-1, in this context a polarized macrophage can act on macrophages in the vicinity through succinate as a metabokine (102,103). Interestingly though, extracellular succinate appears to play a different role to intracellular succinate, as mice with SCNR1 deficiency in macrophages, develop a more aggravated metabolic response to high-fat feeding with a hyperinflammatory profile in AT (103).

αKG is a ketone derivative and intermediate of the TCA cycle, produced by oxidative decarboxylation of isocitrate or by oxidative deamination of glutamate. Several recent studies have revealed important roles of αKG in controlling macrophage polarization through metabolic and epigenetic mechanisms. A high αKG to succinate ratio promotes alternative (M2) activation of macrophages by engaging FAO and acting as a co-factor for the lysine demethylase (KDM)-6B (104). High levels of αKG promote tolerance and resolution of inflammation after M1 polarisation.

Just upstream of the TCA cycle pyruvate dehydrogenase kinase (PDK) hinders the transport of carbon substrates to the TCA cycle by repressing pyruvate dehydrogenase (PDH). This biases towards glycolysis and thus inflammation. Indeed, pharmacologic inhibitors of PDK mitigate inflammatory polarization. In vivo myeloid-deficiency of PDK improves the metabolic phenotype of mice upon high-fat diet with a decrease in AT inflammation and decreased ATM accumulation (105,106).

**Nuclear receptors and transcriptional control of macrophage metabolism**

Main cellular pathways in lipogenesis and lipid metabolism are put in motion by the nuclear receptors PPARγ and PPARβ/δ. Deletion of either protein in macrophages inhibits alternative polarisation in response to IL4 (107). In vivo and upon high fat feeding, similarly the deletion of PPARγ or PPARβ/δ results in mice with an exacerbated metabolic phenotype and increased adipose tissue inflammation (108).

Liver X receptors (LXRs) are also expressed in macrophages, they act as liposensors, regulating intracellular cholesterol content and controlling the expression of efflux transporters
ABCA1 and ABCG1, and apolipoproteins APOE and APOC (109,110). In vitro, LXR ligands inhibit the expression of inflammatory cytokines and promote the expression of arginase (ARG)-2, an enzyme characteristic of alternative polarisation that potentiates the anti-inflammatory response (111).

Sterol regulatory element binding proteins (SREBPs) are the master regulators of lipogenesis, in particular *de novo* lipogenesis, promoting transcription of key enzymes for fatty acid synthesis (e.g. FASN, ACC, SCD1) (112). However, their roles in immune cells are emerging, and have so far proven to be diverse. SREBP1 enhances expression of NLRP1A, a component of the NLRP3 inflammasome that culminates in the release of IL1B as well as being necessary for signalling downstream of TLR4 (113,114). SREBP1a does however have a dual role where it synthesises unsaturated anti-inflammatory fatty acids, or resolvin lipids. Despite its role in the expression of genes that lead to completion of inflammasome assembly, the loss of resolvins has a more important functional effect, where the response to TLR stimulation *in vitro* is of exaggerated inflammation (115). In the context of insulin resistance and T2D, deficiency of, the SREBP target gene, Fatty Acid Synthase (FASN) in macrophages leads to a hyperinflammatory and metabolically perturbed phenotype upon diet-induced obesity. This occurs as FASN plays such a crucial role in producing cellular lipids, including lipids that form the basis of membranes and their downstream signalling. Thus, the lack of FASN resulted in the production of disordered and functionally compromised membranes that aggravated macrophage responses (116). Taken together, these data indicate that lipid metabolism in macrophages is complex and is of considerable functional importance. This field of work is still in its infancy in the domain of T2D and obesity, and could benefit from research into foam cell biology from the fields of atherosclerosis and cardiovascular disease.

**Perspectives and concluding remarks**

Here we have reviewed the roles and regulation of inflammation in the development of insulin resistance and in maladaptive AT function in obesity and T2D. Whilst transcriptional and molecular mechanisms linking inflammation to insulin resistance in AT have been extensively studied, several questions remain unanswered.

The factors that initiate ATM activation remain largely unknown in diabetogenesis. Several cues have been implicated, and are attractive candidates, such as fatty acids, hyperglycaemia or adipocyte death. However, these factors have all also been reported to be aggravated by, or to be downstream of inflammatory polarisation. Thus, defining the metabolic immunogens, or danger signals, that induce sterile inflammation in insulin resistance and T2D is an active area of research.

As we have largely focused on in this review, macrophages undergo extensive bioenergetic and metabolic adaptation to carry out their effector functions. Much progress has been made to determine the fundamental metabolic mechanisms that fuel macrophage polarisation; these early studies have largely been carried in model systems with canonical PRR ligands. Future work could characterise the metabolic requirements of macrophages that populate specific tissue niches as well as macrophage activation in specific disease contexts.

Lastly, the translation aspects of fundamental research must be addressed. To date a major challenge has been in the specific targeting macrophages or other innate immune cells without affecting other cell types. Advances have been made in these domains, such as conjugation of bioactive molecules to antibodies targeting phenotypic cell surface receptors (117).
Abbreviations

T2D  Type-2 diabetes
AT   Adipose tissue
ATM  Adipose tissue macrophages
SVF  Stromal vascular fraction
TNF  Tumour necrosis factor
IRS  Insulin receptor substrate
PI3K Phosphatidylinositol 3-kinase
MAPK Mitogen-activated protein kinase
JNK  c-Jun N-terminal kinase
NFκB Nuclear factor kappa-light-chain-enhancer of activated B cells
PKB  Protein kinase B
IxkB Inhibitors of κB
IL6  Interleukin 6
CCL2/MCP1 Chemokine (C-C motif) ligand 2 / Monocyte chemoattractant protein 1
IKKβ Inhibitor of nuclear factor kappa-B kinase subunit beta
PPR  Pattern recognition receptors
TLR  Toll-like receptors
NLR  NOD-like receptors
DAMP Damage-associated molecular pattern
PAMP Pathogen-associated molecular pattern
NLRP3 Gene encoding NACHT, LRR and PYD domains-containing protein 3
ASC  Apoptosis-associated speck-like protein containing a CARD
IL1B  Interleukin 1 beta
IL18  Interleukin 18
IL1R  Interleukin 1 receptor
MyD88 Myeloid primary response differentiation-88 protein
IRAK  Interleukin 1 associated kinase
JAK  Janus kinase
STAT Signal transducer and activator of transcription
IL4R  Interleukin 4 receptor
TNFR TNF receptor
AMPK AMP-activated protein kinase
IFN  Interferon
IRF  Interferon regulatory factor
GLUT Glucose transporter
HK  Hexokinase
mTORC1 Mammalian target of rapamycin complex
HIF1 Hypoxia inducible factor-1
TCA  tricarboxylic acid cycle
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
CARKL Carbohydrate kinase-like
PPP  Pentose phosphate pathway
NADPH Nicotinamide adenine dinucleotide phosphate
ROS  Reactive oxygen species
MCSF Macrophage colony-stimulating factor
OXPHOS oxidative phosphorylation
FAO  Fatty acid oxidation
IL4  Interleukin 4
LAL Lysosomal acid lipase
FATP1 Fatty acid transporter 1
FABP  Fatty acid binding protein
CPT  Carnitine palmitoyl transferase
αKG Alpha-ketoglutarate
SUCNR1  Succinate receptor
PDH   Pyruvate dehydrogenase
PDK   Pyruvate dehydrogenase kinase
PPAR  Peroxisome proliferator-activated receptor
ABCA1 ATP-binding cassette transporter sub-family A member 1
ABCG1 ATP-binding cassette transporter sub-family G member 1
APOE  Apolipoprotein E
APOC  Apolipoprotein C
ARG2  Arginase-2
SREBP Sterol regulatory element binding protein
NLRP1A Gene encoding NACHT, LRR and PYD domains-containing protein 1A
FASN  Fatty acid synthase

Acknowledgments and Funding:
F.A., L.O. and T.E. were supported by grants from the French National Agency of Research (ANR) for ANR MitoFLAME (ANR-19-CE14-0005) and the European foundation for the study of diabetes (EFSD) / Lilly grant (Characterisation of monocyte metabolism and bioenergetic responses in type-2 diabetes and risk of cardiovascular disease).

Author Contributions
F.A., L.O. and T.E. wrote the manuscript and drew figures.

Author Contributions
The authors declare no conflict of interest

References
1. Bora, P., and Majumdar, A. S. (2017) Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation. Stem Cell Res Ther 8, 145
2. Lumeng, C. N., Deyoung, S. M., and Saltiel, A. R. (2007) Macrophages block insulin action in adipocytes by altering expression of signaling and glucose transport proteins. Am J Physiol Endocrinol Metab 292, E166-174
3. Castoldi, A., Naffah de Souza, C., Camara, N. O., and Moraes-Vieira, P. M. (2015) The Macrophage Switch in Obesity Development. Front Immunol 6, 637
4. Coats, B. R., Schoenfelt, K. Q., Barbosa-Lorenzi, V. C., Peris, E., Cui, C., Hoffman, A., Zhou, G., Fernandez, S., Zhai, L., Hall, B. A., Haka, A. S., Shah, A. M., Reardon, C. A., Brady, M. J., Rhodes, C. J., Maxfield, F. R., and Becker, L. (2017) Metabolically Activated Adipose Tissue Macrophages Perform Detrimental and Beneficial Functions during Diet-Induced Obesity. Cell Rep 20, 3149-3161
5. Hotamisligil, G. S., Shargill, N. S., and Spiegelman, B. M. (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87-91
6. Hotamisligil, G. S., Amer, P., Caro, J. F., Atkinson, R. L., and Spiegelman, B. M. (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95, 2409-2415
7. Uysal, K. T., Wiesbrock, S. M., and Hotamisligil, G. S. (1998) Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity. Endocrinology 139, 4832-4838
8. Shimobayashi, M., Albert, V., Woelnerhanssen, B., Frei, I. C., Weissenberger, D., Meyer-Gersbach, A. C., Clement, N., Moes, S., Colombi, M., Meier, J. A., Swierczynska, M. M., Jeno, P., Beglinger, C., Peterli, R., and Hall, M. N. (2018) Insulin resistance causes inflammation in adipose tissue. J Clin Invest 128, 1538-1550
9. Lee, Y. S., Li, P., Huh, J. Y., Hwang, I. J., Lu, M., Kim, J. I., Ham, M., Talukdar, S., Chen, A., Lu, W. J., Bandypadhyay, G. K., Schwendener, R., Olefsky, J., and Kim, J. B. (2011) Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes 60, 2474-2483

10. Khamzina, L., Gruppuso, P. A., and Wands, J. R. (2003) Insulin signaling through insulin receptor substrate 1 and 2 in normal liver development. Gastroenterology 125, 572-585

11. Dandona, P., Weinstock, R., Thusu, K., Abdel-Rahman, E., Ajlada, A., and Wadden, T. (1998) Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 83, 2907-2910

12. Kern, P. A., Ranganathan, S., Li, C., Wood, L., and Ranganathan, G. (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280, E745-751

13. Dalmas, E., Toubal, A., Alzaied, F., Blazek, K., Eames, H. L., Lebozec, K., Pini, M., Hainault, I., Montastier, E., Denis, R. G., Ancel, P., Lacombe, A., Ling, Y., Allatif, O., Cruciani-Guglielmacci, C., Andre, S., Viguerie, N., Poitou, C., Stich, V., Torcivia, A., Foufelle, F., Luquet, S., Aron-Wisnewsky, J., Langin, D., Clement, K., Udalova, I. A., and Ventecl, F. (2015) Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity. Nat Med 21, 610-618

14. Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li, Z. W., Karin, M., and Shoelson, S. E. (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikktbeta. Science 293, 1673-1677

15. Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., and Petersen, K. F. (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51, 797-802

16. Drarreni, K., Gautier, J. F., Ventecl, N., and Alzaid, F. (2019) Transcriptional control of macrophage polarisation in type 2 diabetes. Semin Immunopathol 41, 515-529

17. Nakatani, Y., Kaneto, H., Kawamori, D., Hatazaki, M., Miyatsuka, T., Matsuoka, T. A., Kajimoto, Y., Matsuhashi, M., Yamasaki, Y., and Hori, M. (2004) Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 279, 45803-45809

18. Bluher, M., Bashan, N., Shai, I., Harman-Boehm, I., Tarnovscky, T., Avinaoeh, E., Durnovall, M., Dietrich, A., Kloting, N., and Rudich, A. (2009) Activated Ask1-MKK4-p38MAPK/JNK stress signaling pathway in human omental fat tissue may link macrophage infiltration to whole-body Insulin sensitivity. J Clin Endocrinol Metab 94, 2507-2515

19. Baker, R. G., Hayden, M. S., and Ghosh, S. (2011) NF-kappaB, inflammation, and metabolic disease. Cell Metab 13, 11-22

20. Surmi, B. K., and Hasty, A. H. (2008) Macrophage infiltration into adipose tissue: initiation, propagation and remodeling. Future Lipidol 3, 545-556

21. Haase, J., Weyer, U., Immig, K., Kloting, N., Bluher, M., Eilers, J., Bechmann, I., and Gericke, M. (2014) Local proliferation of macrophages in adipose tissue during obesity-induced inflammation. Diabetologia 57, 562-571

22. Solinas, G., Naugler, W., Galimi, F., Lee, M. S., and Karin, M. (2006) Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci U S A 103, 16454-16459

23. Ozcan, U., Cao, Q., Yilmaz, E., Lee, A. H., Iwakoshi, N. N., Ozdelen, E., Tuncman, G., Gorgun, C., Glimcher, L. H., and Hotamisligil, G. S. (2004) Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306, 457-461

24. Aguirre, V., Uchida, T., Yenush, L., Davis, R., and White, M. F. (2000) The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 275, 9047-9054

25. Tanti, J. F., Gremaux, T., Van Obberghen, E., and Le Marchand-Brustel, Y. (1994) Insulin receptor substrate 1 is phosphorylated by the serine kinase activity of phosphatidylinositol 3-kinase. Biochem J 304 ( Pt 1), 17-21
26. Gual, P., Le Marchand-Brustel, Y., and Tanti, J. F. (2005) Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. *Biochimie* **87**, 99-109

27. Regnier, C. H., Song, H. Y., Gao, X., Goeddel, D. V., Cao, Z., and Rothe, M. (1997) Identification and characterization of an IkappaB kinase. *Cell* **90**, 373-383

28. Covert, M. W., Leung, T. H., Gaston, J. E., and Baltimore, D. (2005) Achieving stability of lipopolysaccharide-induced NF-kappaB activation. *Science* **309**, 1854-1857

29. Jiao, P., Ma, J., Feng, B., Zhang, H., Diehl, J. A., Chin, Y. E., Yan, W., and Xu, H. (2011) FFA-induced adipocyte inflammation and insulin resistance: involvement of ER stress and IKKbeta pathways. *Obesity (Silver Spring)* **19**, 483-491

30. Orliaguet, L., Dalmas, E., Drareni, K., Venteclcf, N., and Alzaid, F. (2020) Mechanisms of Macrophage Polarization in Insulin Signaling and Sensitivity. *Front Endocrinol (Lausanne)* **11**, 62

31. Vandanmagsar, B., Youm, Y. H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., and Dixit, V. D. (2011) The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. *Nat Med* **17**, 179-188

32. Schroder, K., Zhou, R., and Tschopp, J. (2010) The NLRP3 inflammasome: a sensor for metabolic danger? *Science* **327**, 296-300

33. Donath, M. Y., Schumann, D. M., Faulenbach, M., Ellingsgaard, H., Perren, A., and Ehres, J. A. (2008) Islet inflammation in type 2 diabetes: from metabolic stress to therapy. *Diabetes Care* **31 Suppl 2**, S161-164

34. Lagathu, C., Yvan-Charvet, L., Bastard, J. P., Maachi, M., Quignard-Boulange, A., Capeau, J., and Caron, M. (2006) Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. *Diabetologia* **49**, 2162-2173

35. Gao, D., Madi, M., Ding, C., Fok, M., Steele, T., Ford, C., Hunter, L., and Bing, C. (2014) Interleukin-1beta mediates macrophage-induced impairment of insulin signaling in human primary adipocytes. *Am J Physiol Endocrinol Metab* **307**, E289-304

36. Ballak, D. B., Stienstra, R., Tack, C. J., Dinarello, C. A., and van Diepen, J. A. (2015) IL-1 family members in the pathogenesis and treatment of metabolic disease: Focus on adipose tissue inflammation and insulin resistance. *Cytokine* **75**, 280-290

37. Wood, I. S., Wang, B., Jenkins, J. R., and Trayhurn, P. (2005) The pro-inflammatory cytokine IL-18 is expressed in human adipose tissue and strongly upregulated by TNFalpha in human adipocytes. *Biochem Biophys Res Commun* **337**, 422-429

38. Zilverschoon, G. R., Tack, C. J., Joosten, L. A., Kullberg, B. J., van der Meer, J. W., and Netea, M. G. (2008) Interleukin-18 resistance in patients with obesity and type 2 diabetes mellitus. *Int J Obes (Lond)* **32**, 1407-1414

39. Harms, R. Z., Creer, A. J., Lorenzo-Arteaga, K. M., Ostlund, K. R., and Sarvetnick, N. E. (2017) Interleukin (IL)-18 Binding Protein Deficiency Disrupts Natural Killer Cell Maturation and Diminishes Circulating IL-18. *Front Immunol* **8**, 1020

40. Feve, B., and Bastard, J. P. (2009) The role of interleukins in insulin resistance and type 2 diabetes mellitus. *Nat Rev Endocrinol* **5**, 305-311

41. Dodington, D. W., Desai, H. R., and Woo, M. (2018) JAK/STAT - Emerging Players in Metabolism. *Trends Endocrinol Metab* **29**, 55-65

42. Lagathu, C., Bastard, J. P., Auclair, M., Maachi, M., Capeau, J., and Caron, M. (2003) Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. *Biochem Biophys Res Commun* **311**, 372-379

43. Perry, R. J., Cardone, R. L., Petersen, M. C., Zhang, D., Fouqueray, P., Hallakou-Bozec, S., Bolze, S., Shulman, G. I., Petersen, K. F., and Kibbey, R. G. (2016) Imeiglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. *Am J Physiol Endocrinol Metab* **311**, E461-470

44. Perry, R. J., Camporez, J. G., Kursawe, R., Titchell, P. M., Zhang, D., Perry, C. J., Jurczak, M. J., Abudukadier, A., Han, M. S., Zhang, X. M., Ruan, H. B., Yang, X., Caprio, S., Kaech, S. M., Sul, H. S., Birnbaum, M. J., Davis, R. J., Cline, G. W., Petersen, K. F., and Shulman, G. I. (2015) Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. *Cell* **160**, 745-758
45. Sabio, G., Das, M., Mora, A., Zhang, Z., Jun, J. Y., Ko, H. J., Barrett, T., Kim, J. K., and Davis, R. J. (2008) A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. *Science* **322**, 1539-1543

46. Beutler, B., Greenwald, D., Hulmes, J. D., Chang, M., Pan, Y. C., Mathison, J., Ulevitch, R., and Cerami, A. (1985) Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. *Nature* **316**, 552-554

47. Torti, F. M., Dieckmann, B., Beutler, B., Cerami, A., and Ringold, G. M. (1985) A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. *Science* **229**, 867-869

48. Gatanaga, T., Hwang, C. D., Kohr, W., Cappuccini, F., Lucci, J. A., 3rd, Jeffes, E. W., Lentz, R., Tomich, J., Yamamoto, R. S., and Granger, G. A. (1990) Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. *Proc Natl Acad Sci U S A* **87**, 8781-8784

49. Peraldi, P., Hotamisligil, G. S., Buurman, W. A., White, M. F., and Spiegelman, B. M. (1996) Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. *J Biol Chem* **271**, 13018-13022

50. Hotamisligil, G. S., Amer, P., Atkinson, R. L., and Spiegelman, B. M. (1997) Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. *Diabetes* **46**, 451-455

51. Pandey, M., Tuncman, G., Hotamisligil, G. S., and Samad, F. (2003) Divergent roles for p55 and p75 TNF-alpha receptors in the induction of plasminogen activator inhibitor-1. *Am J Pathol* **162**, 933-941

52. Caithorn, W. P., and Sethi, J. K. (2008) TNF-alpha and adipocyte biology. *FEBS Lett* **582**, 117-131

53. Nisoli, E., Briscini, L., Giordano, A., Tonello, C., Wiesbrock, S. M., Uysal, K. T., Cinti, S., Carruba, M. O., and Hotamisligil, G. S. (2000) Tumor necrosis factor alpha mediates apoptosis of brown adipocytes and defective brown adipocyte function in obesity. *Proc Natl Acad Sci U S A* **97**, 8033-8038

54. Kim, K. Y., Kim, J. K., Jeon, J. H., Yoon, S. R., Choi, I., and Yang, Y. (2005) c-Jun N-terminal kinase is involved in the suppression of adiponectin expression by TNF-alpha in 3T3-L1 adipocytes. *Biochem Biophys Res Commun* **327**, 460-467

55. Chae, G. N., and Kwak, S. J. (2003) NF-kappaB is involved in the TNF-alpha induced inhibition of the differentiation of 3T3-L1 cells by reducing PPARgamma expression. *Exp Mol Med* **35**, 431-437

56. Stephens, J. M., Lee, J., and Pilch, P. F. (1997) Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. *J Biol Chem* **272**, 971-976

57. Ruan, H., Miles, P. D., Ladd, C. M., Ross, K., Golub, T. R., Olefsky, J. M., and Lodish, H. F. (2002) Profiling gene transcription in vivo reveals adipose tissue as an immediate target of tumor necrosis factor-alpha: implications for insulin resistance. *Diabetes* **51**, 3176-3188

58. Ruan, H., Hacohen, N., Golub, T. R., Van Parjis, L., and Lodish, H. F. (2002) Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-kappaB activation by TNF-alpha is obligatory. *Diabetes* **51**, 1319-1336

59. Schindler, C., and Darnell, J. E., Jr. (1995) Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. *Annu Rev Biochem* **64**, 621-651

60. Richard, A. J., and Stephens, J. M. (2011) Emerging roles of JAK-STAT signaling pathways in adipocytes. *Trends Endocrinol Metab* **22**, 325-332

61. Richard, A. J., and Stephens, J. M. (2014) The role of JAK-STAT signaling in adipose tissue function. *Biochim Biophys Acta* **1842**, 431-439

62. Gurzov, E. N., Stanley, W. J., Pappas, E. G., Thomas, H. E., and Gough, D. J. (2016) The JAK/STAT pathway in obesity and diabetes. *FEBS J* **283**, 3002-3015
63. Filgueiras, L. R., Brandt, S. L., Ramalho, T. R., Jancar, S., and Serezani, C. H. (2017) Imbalance between HDAC and HAT activities drives aberrant STAT1/MyD88 expression in macrophages from type 1 diabetic mice. *J Diabetes Complications* **31**, 334-339

64. Vasamsetti, S. B., Kannewar, S., Kanugula, A. K., Thatipalli, A. R., Kumar, J. M., and Kotamraju, S. (2015) Metformin inhibits monocyte-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. *Diabetes* **64**, 2028-2041

65. Desai, H. R., Sivasubramaniyam, T., Revelo, X. S., Schroer, S. A., Luk, C. T., Rikkala, P. R., Methereal, A. H., Dodington, D. W., Park, Y. J., Kim, M. J., Rapps, J. A., Besla, R., Robbins, C. S., Wagner, K. U., Bazinet, R. P., Winer, D. A., and Woo, M. (2017) Macrophage JAK2 deficiency protects against high-fat diet-induced inflammation. *Sci Rep* **7**, 7653

66. Sajic, T., Hainard, A., Scherl, A., Wohlwend, A., Negro, F., Sanchez, J. C., and Szanto, I. (2013) STAT6 promotes bi-directional modulation of PKM2 in liver and adipose inflammatory cells in rosiglitazone-treated mice. *Sci Rep* **3**, 2350

67. Balkwill, F. R. (1986) Interferons: from molecular biology to man. Part 1. Genetics and molecular biology of the interferon system. *Microbiol Sci* **3**, 212-215

68. Kumaran Satyanarayanan, S., El Kebir, D., Soboh, S., Butenko, S., Sekheri, M., Saadi, J., Peled, N., Assi, S., Othman, A., Schif-Zuck, S., Feuermann, Y., Barkan, D., Sher, N., Filep, J. G., and Ariel, A. (2019) IFN-beta is a macrophage-derived effector cytokine facilitating the resolution of bacterial inflammation. *Nat Commun* **10**, 3471

69. Zhao, G. N., Jiang, D. S., and Li, H. (2015) Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease. *Biochim Biophys Acta* **1852**, 365-378

70. Chen, W., and Royer, W. E., Jr. (2010) Structural insights into interferon regulatory factor activation. *Cell Signal* **22**, 883-887

71. Orr, J. S., Puglisi, M. J., Ellacott, K. L., Lumeng, C. N., Wasserman, D. H., and Hasty, A. H. (2012) Toll-like receptor 4 deficiency promotes the alternative activation of adipose tissue macrophages. *Diabetes* **61**, 2718-2727

72. Eguchi, J., Kong, X., Tenta, M., Wang, X., Kang, S., and Rosen, E. D. (2013) Interferon regulatory factor 4 regulates obesity-induced inflammation through regulation of adipose tissue macrophage polarization. *Diabetes* **62**, 3394-3403

73. Eguchi, J., Wang, X., Yu, S., Kershaw, E. E., Chiu, P. C., Dushay, J., Estall, J. L., Klein, U., Maratos-Flier, E., and Rosen, E. D. (2011) Transcriptional control of adipose lipid handling by IRF4. *Cell Metab* **13**, 249-259

74. Freermerman, A. J., Johnson, A. R., Sacks, G. N., Milner, J. J., Kirk, E. L., Troester, M. A., Macintyre, A. N., Goraksha-Hicks, P., Rathmell, J. C., and Makowski, L. (2014) Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. *J Biol Chem* **289**, 7884-7896

75. Nishizawa, T., Kanter, J. E., Kramer, F., Barnhart, S., Shen, X., Vivekanandand-Giri, A., Wall, V. Z., Kowitz, J., Devaraj, S., O’Brien, K. D., Pennathur, S., Tang, J., Miyaoaka, R. S., Raines, E. W., and Bornfeldt, K. E. (2014) Testing the role of myeloid cell glucose flux in inflammation and atherosclerosis. *Cell Rep* **7**, 356-365

76. Moon, J. S., Hisata, S., Park, M. A., DeNicola, G. M., Ryter, S. W., Nakahira, K., and Choi, A. M. K. (2015) mTORC1-Induced HK1-Dependent Glycolysis Regulates NLRP3 Inflammasome Activation. *Cell Rep* **12**, 102-115

77. Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson-McDermott, E. M., McGettrick, A. F., Goel, G., Frezza, C., Bernard, N. J., Kelly, B., Foley, N. H., Zheng, L., Gardet, A., Tong, Z., Jany, S. S., Corr, S. C., Haneklaus, M., Caffrey, B. E., Pierce, K., Walmesley, S., Beasley, F. C., Cummins, E., Nizet, V., Whyte, M., Taylor, C. T., Lin, H., Masters, S. L., Gottlieb, E., Kelly, V. P., Clish, C., Auron, P. E., Xavier, R. J., and O’Neill, L. A. (2013) Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. *Nature* **496**, 238-242

78. Koo, S. J., and Garg, N. J. (2019) Metabolic programming of macrophage functions and pathogens control. *Redox Biol* **24**, 101198
79. Palsson-McDermott, E. M., Curtis, A. M., Goel, G., Lauterbach, M. A. R., Sheedy, F. J., Gleeson, L. E., van den Bosch, M. W. M., Quinn, S. R., Domingo-Fernandez, R., Johnston, D. G. W., Jiang, J. K., Israelsen, W. J., Keane, J., Thomas, C., Clish, C., Vander Heiden, M., Xavier, R. J., and O’Neill, L. A. J. (2015) Pyruvate Kinase M2 Regulates Hif-1alpha Activity and IL-1beta Induction and Is a Critical Determinant of the Warburg Effect in LPS-Activated Macrophages. *Cell Metab* 21, 347

80. Millet, P., Vachharajani, V., McPhail, L., Yoza, B., and McCall, C. E. (2016) GAPDH Binding to TNF-alpha mRNA Contributes to Posttranscriptional Repression in Monocytes: A Novel Mechanism of Communication between Inflammation and Metabolism. *J Immunol* 196, 2541-2551

81. Jha, A. K., Huang, S. C., Sergushichev, A., Lampropoulou, V., Ivanova, Y., Loginicheva, E., Chmielewski, K., Stewart, K. M., Ashall, J., Everts, B., Pearce, E. J., Driggers, E. M., and Artyomov, M. N. (2015) Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. *Immunity* 42, 419-430

82. Seneviratne, A. N., Edsfeldt, A., Cole, J. E., Kassiteridi, C., Swart, M., Park, I., Green, P., Khoyratty, T., Saliba, D., Goddard, M. E., Sansom, S. N., Goncalves, I., Krams, R., Udalova, I. A., and Monaco, C. (2017) Interferon Regulatory Factor 5 Controls Necrotic Core Formation in Atherosclerotic Lesions by Impairing Efferocytosis. *Circulation* 136, 1140-1154

83. Hedl, M., Yan, J., and Abraham, C. (2016) IRF5 and IRF5 Disease-Risk Variants Increase Glycolysis and Human M1 Macrophage Polarization by Regulating Proximal Signaling and Akt2 Activation. *Cell Reports* 16, 2442-2455

84. Huang, S. C. C., Smith, A. M., Everts, B., Colonna, M., Pearce, E. L., Schilling, J. D., and Pearce, E. J. (2016) Metabolic Reprogramming Mediated by the mTORC2-IRF4 Signaling Axis Is Essential for Macrophage Alternative Activation. *Immunity* 45, 817-830

85. Tan, Z., Xie, N., Cui, H. C., Krams, R., Moellerling, D. R., Abraham, E., Thannickal, V. J., and Liu, G. (2015) Pyruvate Dehydrogenase Kinase 1 Participates in Macrophage Polarization via Regulating Glucose Metabolism. *Journal of Immunology* 194, 6082-6089

86. de Mello, A. H., Costa, A. B., Engel, J. D. G., and Rezin, G. T. (2018) Mitochondrial dysfunction in obesity. *Life Sciences* 192, 26-32

87. Yin, X., Lanza, I. R., Swain, J. M., Sarr, M. G., Nair, K. S., and Jensen, M. D. (2014) Adipocyte Mitochondrial Function Is Reduced in Human Obesity Independent of Fat Cell Size. *J Clin Endocr Metab* 99, E209-E216

88. Escames, G., Lopez, L. C., Garcia, J. A., Garcia-Corzo, L., Ortiz, F., and Acuna-Castroviejo, D. (2012) Mitochondrial DNA and inflammatory diseases. *Hum Genet* 131, 161-173

89. Lopez-Armada, M. J., Riveiro-Naveira, R. R., Vaamonde-Garcia, C., and Valcarcel-Ares, M. N. (2013) Mitochondrial dysfunction and the inflammatory response. *Mitochondrion* 13, 106-118

90. Heilbronn, L., Smith, S. R., and Ravussin, E. (2004) Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. *Int J Obes Relat Metab Disord* 28 Suppl 4, S12-21

91. Tsao, C. H., Shiau, M. Y., Chuang, P. H., Chang, Y. H., and Hwang, J. (2014) Interleukin-4 regulates lipid metabolism by inhibiting adipogenesis and promoting lipolysis. *J Lipid Res* 55, 385-397

92. Namgaladze, D., and Brune, B. (2016) Macrophage fatty acid oxidation and its roles in macrophage polarization and fatty acid-induced inflammation. *Biochim Biophys Acta* 1861, 1796-1807

93. Nomura, M., Liu, J., Rovira, II, Gonzalez-Hurtado, E., Lee, J., Wolfgang, M. J., and Finkel, T. (2016) Fatty acid oxidation in macrophage polarization. *Nat Immunol* 17, 216-217

94. Vats, D., Mukundan, L., Odegaard, J. I., Zhang, L., Smith, K. L., Morel, C. R., Wagner, R. A., Greaves, D. R., Murray, P. J., and Chawla, A. (2006) Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. *Cell Metab* 4, 13-24
95. Huang, S. C., Everts, B., Ivanova, Y., O’Sullivan, D., Nascimento, M., Smith, A. M., Beatty, W., Love-Gregory, L., Lam, W. Y., O’Neill, C. M., Yan, C., Du, H., Abumrad, N. A., Urban, J. F., Jr., Artyomov, M. N., Pearce, E. L., and Pearce, E. J. (2014) Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. *Nat Immunol* **15**, 846-855

96. Furuhashi, M., Fucho, R., Gorgun, C. Z., Tuncman, G., Cao, H., and Hotamisligil, G. S. (2008) Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. *J Clin Invest* **118**, 2640-2650

97. Calle, P., Munoz, A., Sola, A., and Hotter, G. (2019) CPT1a gene expression reverses the inflammatory and anti-phagocytic effect of 7-ketocholesterol in RAW264.7 macrophages. *Lipids Health Dis* **18**, 215

98. Namgaladze, D., and Brune, B. (2014) Fatty acid oxidation is dispensable for human macrophage IL-4-induced polarization. *Biochim Biophys Acta* **1841**, 1329-1335

99. Zaslona, Z., Serezani, C. H., Okunishi, K., Aronoff, D. M., and Peters-Golden, M. (2012) Prostaglandin E2 restrains macrophage maturation via E prostanoid receptor 2/protein kinase A signaling. *Blood* **119**, 2358-2367

100. Lampropoulou, V., Sergushichev, A., Bambouskova, M., Nair, S., Vincent, E. E., Loginicheva, E., Cervantes-Barragan, L., Ma, X., Huang, S. C., Griss, T., Weinheimer, C. J., Khader, S., Randolph, G. J., Pearce, E. J., Jones, R. G., Diwan, A., Diamond, M. S., and Artyomov, M. N. (2016) Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling and Regulation of Inflammation. *Cell Metab* **24**, 158-166

101. Mills, E. L., Kelly, B., Logan, A., Costa, A. S. H., Varma, M., Bryant, C. E., Tourloniousis, P., Dabritz, J. H. M., Gottlieb, E., Latorre, I., Corr, S. C., McManus, G., Ryan, D., Jacobs, H. T., Szibor, M., Xavier, R. J., Braun, T., Frezza, C., Murphy, M. P., and O’Neill, L. A. (2016) Succinate Dehydrogenase Supports Metabolic Repurposing of Mitochondria to Drive Inflammatory Macrophages. *Cell* **167**, 457-470 e413

102. Littlewood-Evans, A., Sarret, S., Apfel, V., Loesle, P., Dawson, J., Zhang, J., Muller, A., Tigani, B., Kneuer, R., Patel, S., Valeaux, S., Gommernann, N., Rubic-Schneider, T., Junt, T., and Carballido, J. M. (2016) GPR91 senses extracellular succinate released from inflammatory macrophages and exacerbates rheumatoid arthritis. *J Exp Med* **213**, 1655-1662

103. Keiran, N., Ceperuelo-Mallafre, V., Calvo, E., Hernandez-Alvarez, M. I., Ejarque, M., Nunez-Roa, C., Horrillo, D., Maymo-Masip, E., Rodriguez, M. M., Fradera, R., de la Rosa, J. V., Jorba, R., Egia, A., Zorzano, A., Medina-Gomez, G., Serena, C., Castrillo, A., Vendrell, J., and Fernandez-Velado, S. (2019) SUCNR1 controls an anti-inflammatory program in macrophages to regulate the metabolic response to obesity. *Nat Immunol* **20**, 581-592

104. Liu, P. S., Wang, H., Li, X., Chao, T., Teav, T., Christen, S., Di Conza, G., Cheng, W. C., Chou, C. H., Vavakova, M., Muret, C., Debackere, K., Mazzone, M., Huang, H. D., Fendt, S. M., Ivanisevic, J., and Ho, P. C. (2017) alpha-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. *Nat Immunol* **18**, 985-994

105. Min, B. K., Park, S., Kang, H. J., Kim, D. W., Ham, H. J., Ha, C. M., Choi, B. J., Lee, J. Y., Oh, C. J., Yoo, E. K., Kim, H. E., Kim, B. G., Jeon, J. H., Hyeon, D. Y., Hwang, D., Kim, Y. H., Lee, C. H., Lee, T., Kim, J. W., Choi, Y. K., Park, K. G., Chawla, A., Lee, J., Harris, R. A., and Lee, I. K. (2019) Pyruvate Dehydrogenase Kinase Is a Metabolic Checkpoint for Polarization of Macrophages to the M1 Phenotype. *Front Immunol* **10**, 944

106. Meiser, J., Kramer, L., Sacariu, S. C., Battello, N., Ghelfi, J., D’Herouel, A. F., Skupin, A., and Hiller, K. (2016) Pro-inflammatory Macrophages Sustain Pyruvate Oxidation through Pyruvate Dehydrogenase for the Synthesis of Itaconate and to Enable Cytokine Expression. *J Biol Chem* **291**, 3932-3946

107. Kang, K., Reilly, S. M., Karabacak, V., Gangl, M. R., Fitzgerald, K., Hatano, B., and Lee, C. H. (2008) Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. *Cell Metab* **7**, 485-495
108. Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Red Eagle, A., Vats, D., Brombacher, F., Ferrante, A. W., and Chawla, A. (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. *Nature* **447**, 1116-1120

109. Venkateswaran, A., Laffitte, B. A., Joseph, S. B., Mak, P. A., Wilpitz, D. C., Edwards, P. A., and Tontonoz, P. (2000) Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRalpha. *Proc Natl Acad Sci U S A* **97**, 12097-12102

110. Joseph, S. B., Bradley, M. N., Castrillo, A., Bruhn, K. W., Mak, P. A., Pei, L., Hogenesch, J., O’Connell R, M., Cheng, G., Saez, E., Miller, J. F., and Tontonoz, P. (2004) LXR-dependent gene expression is important for macrophage survival and the innate immune response. *Cell* **119**, 299-309

111. Marathe, C., Bradley, M. N., Hong, C., Lopez, F., Ruiz de Galarreta, C. M., Tontonoz, P., and Castrillo, A. (2006) The arginase II gene is an anti-inflammatory target of liver X receptor in macrophages. *J Biol Chem* **281**, 32197-32206

112. Im, S. S., Yousef, L., Blaschitz, C., Liu, J. Z., Edwards, R. A., Young, S. G., Raffatellu, M., and Osborne, T. F. (2011) Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. *Cell Metab* **13**, 540-549

113. Lee, J. H., Phelan, P., Shin, M., Oh, B. C., Han, X., Im, S. S., and Osborne, T. F. (2018) SREBP-1a-stimulated lipid synthesis is required for macrophage phagocytosis downstream of TLR4-directed mTORC1. *Proc Natl Acad Sci U S A* **115**, E12228-E12234

114. Varghese, J. F., Patel, R., and Yadav, U. C. S. (2019) Sterol regulatory element binding protein (SREBP) -1 mediates oxidized low-density lipoprotein (oxLDL) induced macrophage foam cell formation through NLRI3 inflammasome activation. *Cell Signal* **53**, 316-326

115. Oishi, Y., Spann, N. J., Link, V. M., Muse, E. D., Strid, T., Edillor, C., Kolar, M. J., Matsuzaka, T., Hayakawa, S., Tao, J., Kaikkonen, M. U., Carlin, A. F., Lam, M. T., Manabe, I., Shimano, H., Saghatelian, A., and Glass, C. K. (2017) SREBP1 Contributes to Resolution of Pro-inflammatory TLR4 Signaling by Reprogramming Fatty Acid Metabolism. *Cell Metab* **25**, 412-427

116. Wei, X., Song, H., Yin, L., Rizzo, M. G., Sidhu, R., Covey, D. F., Ory, D. S., and Semenkovich, C. F. (2016) Fatty acid synthesis configures the plasma membrane for inflammation in diabetes. *Nature* **539**, 294-298

117. Nejadmoghaddam, M. R., Minai-Tehrani, A., Ghahremanzadeh, R., Mahmoudi, M., Dinarvand, R., and Zarnani, A. H. (2019) Antibody-Drug Conjugates: Possibilities and Challenges. *Avicenna J Med Biotechnol* **11**, 3-23
Graphical Abstract

Overview of inflammatory changes in adipose tissue with the development of insulin resistance.
Figure 1. Transcriptional and metabolic adaptation of M1-like pro-inflammatory macrophages

Key transcription factors and enzymes that mediate pro-glycolytic and pro-inflammatory mechanisms in M1-like macrophages.
Figure 2. Transcriptional and metabolic adaptation of M2-like anti-inflammatory/pro-resolving macrophages

Key transcription factors and enzymes that mediate oxidative metabolism and immune-regulatory mechanisms in M2-like macrophages.